natgillin/translations-raw huggingface dataset:
Monoaminoxidasehæmmere (MAO-hæmmere): Du må ikke tage Duloxetine Zentiva sammen med en MAO- hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Zentiva if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Monoaminoxidasehæmmere (MAO-hæmmere): Du må ikke tage Xeristar sammen med en MAO- hæmmer eller inden for 14 dage efter afsluttet behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): You should not take Xeristar if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Monoaminoxidasehæmmere (MAO-hæmmere): På grund af risikoen for serotoninsyndrom må duloxetin ikke anvendes sammen med ikke-selektive, irreversible monoaminoxidasehæmmere (MAO- hæmmere) eller i mindst 14 dage efter afbrudt behandling med en MAO-hæmmer.
Monoamine oxidase inhibitors (MAOIs): Due to the risk of serotonin syndrome, duloxetine should not be used in combination with non-selective irreversible monoamine oxidase inhibitors (MAOIs), or within at least 14 days of discontinuing treatment with an MAOI.
Monoaminoxidasehæmmere og malariamidler og antitrypanosomale midler.
Monoamine oxidase inhibitors and anti-malarial and anti-trypanosomal agents.
Monoammoniumglycyrrhizinat
Monoammonium glycyrrhizinate
Monobasisk natriumfosfatmonohydrat Dibasisk natriumfosfatheptahydrat Polysorbat 20
Sodium phosphate monobasic, monohydrate Sodium phosphate dibasic, heptahydrate Polysorbate 20
Monobasisk natriumphosphathydrat Sunset yellow FCF (E110)
Sodium phosphate monobasic hydrate Sunset yellow (E110)
monocytopeni, aplastisk anæmi (pure red cell aplasi), agranulocytose, hæmolyse, hypokoagulation
monocytopenia, pure red cell aplasia, agranulocytosis, haemolysis, hypercoagulation
Monocytter/makrofager aktiveres til drab af tumorceller, granulocytter aktiveres til at udvise øget fagocytisk aktivitet, ”respiratorisk brist” og degranulering, og adhæsion til endotelium.
T-cells and immunoglobulin-secreting cells is enhanced, monocytes/macrophages are activated for killing of tumour cells, granulocytes are activated to display enhanced phagocytic activity, respiratory burst and degranulation, and adherence to endothelium.
Monoklonale antistoffer er proteiner der genkender og binder til andre unikke proteiner.
Monoclonal antibodies are proteins that recognise and bind to other unique proteins.
Monoklonale antistoffer er proteiner, der genkender og binder sig specifikt til bestemte proteiner i kroppen.
Monoclonal antibodies are proteins that recognise and bind specifically to certain proteins in the body.
monokomponent-
interaction seen.
Mononatrium-L-glutamatmonohydrat Dinatriumphosphat
Monosodium L-glutamate monohydrate Disodium phosphate
Mononatriumglutamatmonohydrat Vand til injektionsvæsker
Monosodium glutamate monohydrate Water for injections
Mononeuropatier, koma§
Mononeuropathies, coma§
Mononukleære celler fra perifert blod, opsamlet fra patienterne, dyrkes med PAP-GM-CSF, et fusionsprotein bestående af PAP knyttet til granulocyt/makrofag-kolonistimulerende faktor (GM- CSF), som er en immunaktivator.
Peripheral blood mononuclear cells collected from the patients are cultured with PAP-GM-CSF, a fusion protein consisting of PAP linked to granulocyte-macrophage colony-stimulating factor (GM-CSF) an immune cell activator.
Monophosphatmetabolitten omdannes derefter til den aktive 5’-triphosphat fra ara-GTP.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate form, ara-GTP.
Monophosphatmetabolitten omdannes derefter til den aktive 5’-triphosphat fra ara-GTP.
The monophosphate metabolite is subsequently converted to the active 5’-triphosphate from, ara-GTP.
Monotard 100 IE/ml
Monotard 100 IU/ml
Monotard 100 IE/ml Injektionsvæske, suspension Insulin human, rDNA
Monotard 100 IU/ml Suspension for injection Insulin human, rDNA
Monotard 40 IE/ml
Monotard 40 IU/ml
Monotard 40 IE/ml Injektionsvæske, suspension Insulin human, rDNA
Monotard 40 IU/ml Suspension for injection Insulin human, rDNA
Monotard er en langtidsvirkende insulin, som kan gives en eller to gange dagligt som injektion med eller uden en hurtigt virkende insulin (til måltider), alt efter hvad lægen anbefaler.
Monotard is a long-acting insulin, it can be given as a once daily or twice daily injection, with or without a fast-acting insulin (at meal times), according to the doctor’s recommendation.
Monotard er en langtidsvirkende insulintype.
Monotard is a long-acting insulin.
Monotard indeholder også zinkchlorid, zinkacetat, natriumchlorid, methylparahydroxybenzoat, natriumacetat, natriumhydroxid, saltsyre og vand til injektionsvæsker.
Monotard also contains zinc chloride, zinc acetate, sodium chloride, methyl parahydroxy benzoate, sodium acetate, sodium hydroxide, hydrochloric acid and water for injections.
Monotard indeholder også zinkchlorid, zinkacetat, natriumchlorid, methylparahydroxybenzoat, natriumacetat, natriumhydroxid, saltsyre og vand til injektionsvæsker.
Monotard also contains zinc chloride, zinc acetate, sodium chloride, methyl parahydroxy benzoate, sodium actetate, sodium hydroxide, hydrochloric acid and water for injections.
Monoterapi
60.3
Monoterapi
Mono- therapy
Monoterapi ((ovariekarcinom og småcellet lungecancer)
Monotherapy (Ovarian and Small cell lung carcinoma)
Monoterapi (26 uger)
Monotherapy (26 weeks)
Monoterapi (ovariekarcinom og småcellet lungecancer)
Monotherapy (Ovarian and Small cell lung carcinoma)
Monoterapi (ovariekarcinom og småcellet lungecancer):
Monotherapy (ovarian and small cell lung carcinoma)
monoterapi i op til 4 uger
monotherapy with short-term duration of up to 4 weeks
monoterapi i ≥ 12 uger
monotherapy with ≥ 12 week duration
Monoterapi med capecitabin efter svigt af taxaner og kemoterapi, som indeholder antracykliner, og af patienter til hvem behandling med antracykliner ikke er indiceret
Monotherapy with capecitabine after failure of taxanes, anthracycline containing chemotherapy, and for whom anthracycline therapy is not indicated
Monoterapi med capecitabin i metastatisk kolorektalkræft
Monotherapy with capecitabine in metastatic colorectal cancer
Monoterapi med capecitabin ved metastatisk kolorektalkræft
Monotherapy with capecitabine in metastatic colorectal cancer
Monoterapi med PegIntron og 2-stofsbehandling med PegIntron og ribavirin: Behandlingsnaive patienter
Monotherapy with PegIntron and bitherapy with PegIntron and ribavirin Naïve patients
Monoterapi med PegIntron og 2-stofsbehandling med PegIntron og ribavirin: Behandlingsnaive patienter
Monotherapy with PegIntron and bitherapy with PegIntron and ribavirin: Naïve patients
Monoterapi med ViraferonPeg og 2-stofsbehandling med ViraferonPeg og ribavirin: Behandlingsnaive patienter
Monotherapy with ViraferonPeg and bitherapy with ViraferonPeg and ribavirin Naïve patients
Monoterapi med ViraferonPeg og 2-stofsbehandling med ViraferonPeg og ribavirin: Behandlingsnaive patienter
Monotherapy with ViraferonPeg and bitherapy with ViraferonPeg and ribavirin: Naïve patients
Monoterapi til behandling af hepatitis C bør kun overvejes i tilfælde af kontraindikation mod andre lægemidler.
Monotherapy for hepatitis C should only be considered in cases of contraindication to other medicinal products.
Monoterapi –
Monotherapy
Monoterapi(småcellet lungecancer):
Monotherapy (Small cell lung carcinoma)
Monoterapi-fasen
Monotherapy phase
Monoterapiundersøgelser
Monotherapy Studies
Monothioglycerol 1 mg.
Monothioglycerol 1 mg
Monter sprøjten på Mix2Vial-sættets luer lock-tilkobling ved at dreje med uret , mens hætteglasset med pulver stadig er stående.
While the product vial is upright, connect the syringe to the Mix2Vial´s Luer Lock fitting by screwing clockwise.
Montering af nålen
Attaching the needle
Montering af nålen C
Attaching the needle C
Montér det medfølgende infusionssæt på injektionssprøjten.
Attach the provided infusion set to the syringe.
Mooswaldallee 1 D-79090 Freiburg Tyskland
Mooswaldallee 1 D-79090 Freiburg Germany
Mooswaldallee 1 Freiburg Tyskland
Mooswaldallee 1 Freiburg Germany
Morbiditets- mortalitets- hændelseb
Morbidity- mortality event b
Morbilliformt udslæt eller andet udslæt
Rash morbilliform or other Rash
Morderiske tanker, ændring af mental tilstand§, mani,
Homicidal ideation, mental status change§, mania, bipolar
morfin, fentanyl – anvendes mod smerter
morphine, fentanyl - used for pain
morfinlignende lægemidler, anvendes til at behandle stofafhængighed:
morphine-like medicines, used to treat drug addiction:
Morfinsulfat
Morphine sulphate
morgen og aften)
morning and evening)
Morgendosen skal tages mindst 30 minutter inden morgenmåltidet, mens aftendosen kan tages med eller uden mad.
The morning dose should be taken at least 30 minutes before the morning meal, whereas the evening dose can be taken with or without food.
Morgendosis
Morning Dose
Moroctocog alfa (rekombinant human koagulationsfaktor VIII) IV brug
Moroctocog alfa (recombinant human coagulation factor VIII) IV use
Moroctocog alfa er et glycoprotein med 1438 aminosyrer med en sekvens, som kan sammenlignes med faktor VIII 90 + 80 kDA-formen (dvs.
Moroctocog alfa is a glycoprotein with 1438 amino acids with a sequence that is comparable to the 90 + 80 kDa form of factor VIII (i.e.
Morotocog alfa (rekombinant human koagulationsfaktor VIII) IV brug
Moroctocog alfa (recombinant human coagulation factor VIII) IV use
Morphin Morphinkoncentrationerne kan blive nedsat som følge af induktion af glukurodination forårsaget af samtidigt indgivet ritonavir doseret som et antiretroviralt stof eller som en farmakokinetisk forstærker.
Morphine Morphine levels may be decreased due to induction of glucuronidation by co-administered ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer.
morphin og morphinlignende lægemidler, der anvendes til behandling af stærke smerter (f.eks. methadon, fentanyl);
morphine and morphine-like medicines used to treat severe pain (e.g. methadone, fentanyl);
Morphin, til behandling af stærke smerter.
Morphine, used to treat acute and cancer pain.
Morris Plains, New Jersey 07950 USA
Morris Plains, New Jersey 07950, USA
Mortalitet tilskrevet Candida-infektion
Mortality attributed to Candida infection
Mortalitet uanset årsag
All-cause death
Mortalitet uanset årsag efter 3 år
All cause mortality at 3 years
Mortalitet uanset årsag frem til studiets afslutning (opfølgningsbesøg ved uge 6) var 21/46 (45,7 %).
All-cause mortality up to the end of the study (6 Week Follow-up Visit) was 21/46 (45.7%).
Mortalitet uanset årsag, MI (tavst MI undtaget) eller apopleksi
All cause mortality, MI (excl. silent MI), or stroke
Mortalitet uanset årsag, MI (tavst MI undtaget) eller apopleksi
All-cause mortality, MI (excl. silent MI), or stroke
Mortalitet under forsøgsbehandling
Mortality during study therapy
Mortaliteten i de centrale studier vedrørende dissemineret intravaskulær koagulation (DIC) associeret blødning var meget almindelig (> 10%), hvilket stemmer overens med den tidlige mortalitet, der er rapporteret i litteraturen.
Mortality in the pivotal studies from disseminated intravascular coagulation (DIC) associated haemorrhage was very common (> 10%), which is consistent with the early mortality reported in the literature.
Mortaliteten var højere hos patienter behandlet med 5,3 mg eller 8 mg somatropin dagligt end hos patienter behandlet med placebo, hhv.
Mortality was higher in patients treated with 5.3 or 8 mg somatropin daily compared to patients receiving placebo, 42% vs.
Moskusænder
Muscovy ducks.
Mosswaldallee 1
Mooswaldallee 1
Mosteller-formel: Legemsoverfladeareal (m2) =
Mosteller Formula: BSA (m2) =
Motion Ligesom musklerne har knoglerne brug for motion for at forblive stærke og sunde.
Exercise Like muscles, bones need exercise to stay strong and healthy.
motionerer mere end normalt
exercise more than usual
Motionerer mere end normalt
Exercise more than usual.
Motionerer mere end normalt.
Exercise more than usual.
motionerer mindre end normalt
exercise less than usual
Motivos por los que se recomienda la modificación de las condiciones de la Autorización de Comercialización
Grounds recommending the variation to the terms of the Marketing Authorisation
Motorisk dysfunktion
7 (3.9)
motorisk neuropati (se pkt.
Not known:
motorisk neuropati), svimmelhed,
Peripheral neuropathies (excluding motor neuropathy), Dizziness, Tremor, Dysgeusia, Headache
Motorisk neuropati*, bevidsthedstab (inkl. synkope), svimmelhed*, dysgeusi*, letargi, hovedpine*
Motor neuropathy*, Loss of consciousness (inc syncope), Dizziness*, Dysgeusia*, Lethargy, Headache
motorisk svækkelse (oftest set ved tilfælde af symptomatisk hyperlaktatæmi eller laktatacidose- syndrom) leversvigt
motor weakness (most often reported in the setting of symptomatic hyperlacetatemia or lactic acidosis syndrome) liver failure
Motoriske symptomer (UPDRS del III) blev forbedret med 6,3 ± 1,3 point hos patienter behandlet med rotigotin, og med 5,9 ± 1,3 point i ropinirol-gruppen efter vedligeholdelse i 4 uger.
Motor symptoms (UPDRS Part III) improved by 6.3 ± 1.3 points in rotigotine-treated patients, and by 5.9 ± 1.3 points in the ropinirole- group after 4 weeks of maintenance.
Mouches volantes
Vitreous floaters
mouches volantes, konjunktival blødning
Vitreous floaters; conjunctival hemorrhage
Mouches volantes, øjensmerter, konjunktival blødning
Vitreous floaters, eye pain, conjunctival haemorrhage
Moventig 12,5 mg filmovertrukne tabletter
Moventig 12.5 mg film-coated tablets
Moventig 12,5 mg filmovertrukne tabletter naloxegolum
Moventig 12.5 mg film-coated tablets Naloxegol
Moventig 12,5 mg tabletter fås i aluminiumblistre i pakningsstørrelserne 30 eller 90 filmovertrukne tabletter i blistre uden perforering og 90x1 tabletter i perforerede enkeltdosisblistre.
Moventig 12.5 mg tablets are available in aluminium blisters in pack sizes of 30 or 90 film-coated tablets in non-perforated blisters and 90x1 film-coated tablets in perforated unit dose blisters.
Moventig 12,5 mg tabletter naloxegolum
Moventig 12.5 mg tablets Naloxegol
Moventig 25 mg filmovertrukne tabletter
Moventig 25 mg film-coated tablets
Moventig 25 mg tabletter fås i aluminiumblistre i pakningsstørrelserne 10, 30 eller 90 filmovertrukne tabletter i blistre uden perforering og 90x1 tabletter i perforerede enkeltdosisblistre.
Moventig 25 mg tablets are available in aluminium blisters in pack sizes of 10, 30 or 90 film--coated tablets in non-perforated blisters and 90x1 film-coated tablets in perforated unit dose blisters.
Moventig indeholder:
What Moventig contains
Moventig skal anvendes med forsigtighed hos sådanne patienter.
Moventig should be used with caution in these patients.
Moventig skal tages på tom mave mindst 30 minutter før dagens første måltid eller 2 timer efter dagens første måltid.
Moventig should be taken on an empty stomach at least 30 minutes before the first meal of the day or 2 hours after the first meal.
Moxidectin er aktivt overfor Dirofilaria immitis’s larvestadier (L3, L4) and Dirofilaria repens (L3).
Moxidectin is active against larval stages of Dirofilaria immitis (L3, L4) and Dirofilaria repens (L3).
Moxidectin er aktivt overfor Dirofilaria immitis’s larvestadier (L3, L4).
Moxidectin is active against larval stages (L3, L4) of Dirofilaria immitis.
Moxidectin griber ind i udvekslingen af signaler mellem nerveceller i parasitternes nervesystem (neurotransmission), hvorved nematoder og hjerteorme lammes og dør.
Moxidectin causes paralysis and death of nematodes and heartworms by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites’ nervous system.
Moxidectin interfererer med GABA og glutamat regulerede kloridkanaler.
Moxidectin interacts with GABA and glutamate- gated chloride channels.
Moxifloxacin, til behandling af bakterieinfektioner.
Moxifloxacine, used to treat bacterial infections.
Mozobil 20 mg/ml injektionsvæske, opløsning.
Mozobil 20 mg/ml solution for injection
Mozobil anvendes sammen med et hormon kaldet granulocyt kolonistimulerende faktor (G-CSF).
Mozobil is used together with a hormone called granulocyte colony-stimulating factor (G-CSF).
Mozobil anvendes som hjælp til at løsrive (‘mobilisere’) stamcellerne fra knoglemarven, så de kan frigives i blodet.
Mozobil is used to help dislodge (‘mobilise’) the stem cells from the bone marrow so they can be released into the blood.
Mozobil anvendes som hjælp til indsamling af hæmatopoietiske stamceller (celler i knoglemarven, som kan udvikle sig til forskellige blodcelletyper) til transplantation.
Mozobil is used to help to collect haematopoietic stem cells (cells in the bone marrow that can develop into different types of blood cells) for transplantation.
Mozobil er blevet sammenlignet med placebo (en virkningsløs behandling) i to hovedundersøgelser, som omfattede 298 voksne med en type lymfon kaldet non-Hodgkins lymfom og 302 voksne med multipelt myelom.
Mozobil has been compared with placebo (a dummy treatment) in two main studies involving 298 adults with a type of lymphoma called non-Hodgkin’s lymphoma and 302 adults with multiple myeloma.
Mozobil er en injektionsvæske, der indeholder det aktive stof plerixafor.
Mozobil is a solution for injection that contains the active substance plerixafor.
Mozobil er til subkutan injektion.
Mozobil is for subcutaneous injection.
Mozobil gives som en injektion under huden seks til 11 timer inden hver seance, hvor patientens blod udtages, og stamcellerne udvindes.
Mozobil is given as an injection under the skin, six to 11 hours before each session when the patient’s blood is taken and the stem cells are extracted.
Mozobil indeholder mindre end 1 mmol natrium (23 mg) pr. dosis, dvs. den er i det væsentlige natriumfri.
Mozobil contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.
Mozobil indeholder:
What Mozobil contains
Mozobil leveres som en gennemsigtig, farveløs eller lysegul injektionsvæske, opløsning, i et hætteglas med en latexfri gummiprop.
Mozobil is supplied as a clear colourless or pale yellow solution for injection in a glass vial with a non-latex rubber stopper.
Mozobil må ikke anvendes af personer, der kan være overfølsomme over for nogen af indholdsstofferne.
Mozobil should not be used in people who may be hypersensitive (allergic) to plerixafor or any of the other ingredients.
Mozobil og G-CSF
Mozobil and G-CSF
Mozobil og G-CSF Procentdela (n=144b)
Proportiona in Mozobil and G-CSF (n=144b)
Mozobil og G-CSF Procentdela (n=147b)
Proportiona in Mozobil and G-CSF (n=147b)
Mozobil var mere effektivt end placebo til at mobilisere stamceller fra knoglemarv til blod.
Mozobil was more effective than placebo at mobilising stems cells from the bone marrow into the blood.
Mozobils sikkerhed og virkning til børn under 18 år er endnu ikke fastlagt.
The safety and efficacy of Mozobil in children less than 18 years have not yet been established.
MP 25 mg/m2 oral, dag 1-20
6-MP 25 mg/m2 oral, days 1-20
MP-T
MP MP-T
MPA er en potent, selektiv, ikke- kompetitiv og reversibel inhibitor af inosin-monophosfat-dehydrogenase og hæmmer derfor de novo- vejen for en guanosin-nucleotid- syntese uden inkorporering i DNA.
MPA is a potent, selective, uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase, and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA.
MPAs fordeling afhænger af adskillige transportører.
MPA’s disposition depends on several transporters.
mpone
pon
MPR+R vs.
MPR+R vs MPp+p
MPS I er en heterogen og multisystemisk sygdom, der er karakteriseret ved mangel på -L-iduronidase, en lysosomal hydrolase, der katalyserer hydrolysen for terminale -L-iduroniske rester af dermatansulfat og heparansulfat.
MPS I is a heterogeneous and multisystemic disorder characterised by the deficiency of -L-iduronidase, a lysosomal hydrolase which catalyses the hydrolysis of terminal -L-iduronic residues of dermatan sulfate and heparan sulfate.
MPS IVA er karakteriseret ved fravær eller markant reduktion i N-acetylgalaktosamin-6- sulfatase-aktivitet.
MPS IVA is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity.
MR (0-2 år)
MRI (0-2 years)
MR-billeddiagnostik
MR imaging
MR-scanning).
MRI) should be performed.
MR4.5-rater over tid var konsekvent højere hos dasatinib-behandlede patienter sammenlignet med imatinib-behandlede patienter.
Rates of MR4.5 over time were consistently higher in dasatinib-treated patients compared with imatinib-treated patients.
MRD negativ****
MRD negative
MRD-negativ
MRD negative
MRD-negative (%)
MRD negativee (%)
MRD-positivf (%)
MRD positivef (%)
MRD-status efter induktionsbehandling
MRD status at end of induction treatment
MRI- undersøgelser af de 2 patienter viste hændelser, som var overensstemmende med demyeliserende lidelser i columna cervicalis.
MRI evaluations of the 2 patients demonstrated findings consistent with a demyelinating process in the cervical spine.
MRI-endepunkter (0 - 2 år)
MRI Endpoints (0-2 years)
MRI-endepunkter†
MRI endpoints
MRI-tumorrespons blev evalueret efter RECIST 1.1. Respons ifølge kliniske digitalbilleder blev evalueret efter Verdenssundhedsorganisationens (WHO) tilpassede kriterier [partielt respons (PR): ≥50 % fald i summen af de lodrette diametres produkt (SPD) for en læsion; komplet respons (KR): alle læsioner forsvundet; progressiv sygdom: ≥25 % stigning i læsioners SPD].
MRI tumour response was evaluated by RECIST 1.1. Response by digital clinical photograph was evaluated by World Health Organization (WHO) adapted criteria [partial response (PR): ≥50% decrease in the sum of the product of perpendicular diameters (SPD) of a lesion; complete response (CR): disappearance of all lesions; progressive disease: ≥25% increase in the SPD of lesions].
MRL
MRLs (*)
MRL
No MRL
MRL ikke påkrævet
required
MRL-status
MRL status
MRSA$
MRSA $
MRT
11.6
MRT (time)
MRT (h)
MRT (timer)
Half-life (h)
MS er en nervesygdom, der medfører en betændelseslignende tilstand, som ødelægger det beskyttende lag, der omgiver nerverne (demyelinisering).
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves (demyelination).
MS er en nervesygdom, der medfører en betændelseslignende tilstand, som ødelægger det beskyttende lag, der omgiver nerverne.
MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves.
MS er en nervesygdom, hvor betændelse ødelægger den beskyttende kappe, som omgiver nervecellerne.
MS is a disease of the nerves, in which inflammation destroys the protective sheath surrounding the nerve cells.
MS pseudo-tilbagefald (hyppighed ukendt): Der er en mulighed for, at du i starten af behandlingen med Rebif kan få symptomer, der ligner dem i et multipel sklerose tilbagefald.
MS pseudo-relapse (frequency not known): There is a possibility that at the beginning of your treatment with Rebif you may experience symptoms that resemble those of a multiple sclerosis relapse.
MS-anamnese, år, median (område)
MS-history yrs, median (range)
MS-attak
MS relapse
MS-attak, svimmelhed*, hypæstesi, paræstesi, tremor, dysgeusi*
MS relapse, dizziness*, hypoaesthesia, paraesthesia, tremor, dysgeusia
MSD (Norge) AS Tel: +47 32 20 73 00 msdnorge@msd.no
MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@msd.no
MSD (Norge) AS Tlf: +47 32 20 73 00 msdnorge@ msd.no
MSD Danmark ApS Tlf: + 45 4482 4000 dkmail@merck.com
MSD Danmark ApS Tlf: +45 4482 4000 dkmail@merck.com
MSD Danmark ApS Tlf: +45 44 82 40 00 dkmail@merck.com
MSD Danmark ApS Tlf: +45 4482 4000 dkmail@merck.com
MSD Danmark ApS Tlf: +45 4482 4000 dkmail@merck.com
MSD Danmark ApS Tlf: + 45 4482 4000 dkmail@merck.com
MSD Pharma Hungary Kft, Tel.: + 36.1.888.5300
MSD Pharma Hungary Kft, Tel: + 36.1.888.5300
MSD Pharma Hungary Kft, Tlf: + 36 1 888 5300
MSD Pharma Hungary Kft, Tel: + 36 1 888 5300
MSD Polska Sp. z o.o., Tel.: +48.22.549.51.00
MSD Polska Sp. z o.o., Tel: +48.22.549.51.00
MSD Polska Sp. z o.o., Tlf: +48 22 549 51 00
MSD Polska Sp. z o.o., Tel: +48 22 549 51 00
MSD SHARP & DOHME GMBH Tel: 0800 673 673 673
MSD SHARP & DOHME GMBH
MSD Α. Φ.Β.Ε.Ε.
MSD Α.Φ.Β.Ε.Ε.